Philip T Cagle

Summary

Affiliation: The Methodist Hospital
Country: USA

Publications

  1. doi Lung cancer biomarkers: present status and future developments
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Arch Pathol Lab Med 137:1191-8. 2013
  2. doi Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Arch Pathol Lab Med 137:241-4. 2013
  3. doi Lung cancer genotype-based therapy and predictive biomarkers: present and future
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas, USA
    Arch Pathol Lab Med 136:1482-91. 2012
  4. ncbi Precision medicine for lung cancer: role of the surgical pathologist
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, 6565 Fannin St, Main Building, Room 227, Houston, TX 77030, USA
    Arch Pathol Lab Med 136:1186-9. 2012
  5. doi Diffuse malignant mesothelioma
    Sergio Pina Oviedo
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Arch Pathol Lab Med 136:882-8. 2012
  6. doi Revolution in lung cancer: new challenges for the surgical pathologist
    Philip T Cagle
    Department of Pathology and Laboratory Medicine, 6565 Fannin Street, The Methodist Hospital, Houston, Texas 77030, USA
    Arch Pathol Lab Med 135:110-6. 2011
  7. doi Pathology of the pleura: what the pulmonologists need to know
    Philip T Cagle
    Weill Medical College of Cornell University, New York, New York, USA
    Respirology 16:430-8. 2011
  8. ncbi Review and update of uncommon primary pleural tumors: a practical approach to diagnosis
    Laura Granville
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Arch Pathol Lab Med 129:1428-43. 2005
  9. ncbi EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma
    Wei Zhang
    From the Department of Pathology Dr Zhang, Molecular Diagnostics Laboratory Dr Fan, and Department of Pathology Dr Jagirdar, The University of Texas Health Science Center at San Antonio, and Laboratory Service, Audie L Murphy Memorial Veterans Affairs Medical Center Dr Tio, San Antonio and Department of Pathology and Immunology, Baylor College of Medicine Dr McQuitty, and Department of Pathology and Genomic Medicine, The Methodist Hospital Drs Olsen and Cagle, Ms Hendrickson, and Mr Newton, Houston, Texas
    Arch Pathol Lab Med 138:543-5. 2014
  10. ncbi MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival
    Kun Y Kwon
    Department of Pathology, Baylor College of Medicine, Houston, Tex, USA
    Arch Pathol Lab Med 131:593-8. 2007

Detail Information

Publications31

  1. doi Lung cancer biomarkers: present status and future developments
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Arch Pathol Lab Med 137:1191-8. 2013
    ..Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing...
  2. doi Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Arch Pathol Lab Med 137:241-4. 2013
    ..Folate receptors can serve as targets for drugs attached to folate and are overexpressed in many cancers...
  3. doi Lung cancer genotype-based therapy and predictive biomarkers: present and future
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas, USA
    Arch Pathol Lab Med 136:1482-91. 2012
    ..The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease...
  4. ncbi Precision medicine for lung cancer: role of the surgical pathologist
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, 6565 Fannin St, Main Building, Room 227, Houston, TX 77030, USA
    Arch Pathol Lab Med 136:1186-9. 2012
    ..Pathologists should embrace the innovations described at the Houston Lung Symposium but must recognize that their traditional expertise will be an important component of precision medicine for the foreseeable future...
  5. doi Diffuse malignant mesothelioma
    Sergio Pina Oviedo
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Arch Pathol Lab Med 136:882-8. 2012
    ..It was not until focal invasion into the skeletal muscle was discovered on permanent sections that a diagnosis of DMM could be established...
  6. doi Revolution in lung cancer: new challenges for the surgical pathologist
    Philip T Cagle
    Department of Pathology and Laboratory Medicine, 6565 Fannin Street, The Methodist Hospital, Houston, Texas 77030, USA
    Arch Pathol Lab Med 135:110-6. 2011
    ....
  7. doi Pathology of the pleura: what the pulmonologists need to know
    Philip T Cagle
    Weill Medical College of Cornell University, New York, New York, USA
    Respirology 16:430-8. 2011
    ..These neoplasms are discussed. Also, non-neoplastic pleural diseases, including granulomatous pleuritis, eosinophilic pleuritis and fibrous and fibrinous pleuritis, among other diseases, are discussed...
  8. ncbi Review and update of uncommon primary pleural tumors: a practical approach to diagnosis
    Laura Granville
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Arch Pathol Lab Med 129:1428-43. 2005
    ..Primary pleural tumors are divided according to their behavior and are discussed separately as benign tumors, tumors of low malignant potential, and malignant neoplasms...
  9. ncbi EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma
    Wei Zhang
    From the Department of Pathology Dr Zhang, Molecular Diagnostics Laboratory Dr Fan, and Department of Pathology Dr Jagirdar, The University of Texas Health Science Center at San Antonio, and Laboratory Service, Audie L Murphy Memorial Veterans Affairs Medical Center Dr Tio, San Antonio and Department of Pathology and Immunology, Baylor College of Medicine Dr McQuitty, and Department of Pathology and Genomic Medicine, The Methodist Hospital Drs Olsen and Cagle, Ms Hendrickson, and Mr Newton, Houston, Texas
    Arch Pathol Lab Med 138:543-5. 2014
    ..We investigated the EGFR mutation frequency in primary lung adenocarcinomas in US Hispanics compared with non-Hispanic whites...
  10. ncbi MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival
    Kun Y Kwon
    Department of Pathology, Baylor College of Medicine, Houston, Tex, USA
    Arch Pathol Lab Med 131:593-8. 2007
    ..Although its tissue distribution has been studied, its utility in predicting prognosis in NSCLC is unknown...
  11. doi Differential diagnosis of lung carcinoma with three-dimensional quantitative molecular vibrational imaging
    Liang Gao
    Cornell University, The Methodist Hospital Research Institute, Weill Cornell Medical College, Department of Systems Medicine and Bioengineering, Houston, Texas 77030, USA
    J Biomed Opt 17:066017. 2012
    ....
  12. doi Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma
    Armita Bahrami
    Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    Pathol Int 58:730-4. 2008
    ....
  13. ncbi Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies
    Philip T Cagle
    Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Arch Pathol Lab Med 129:1421-7. 2005
    ....
  14. doi Differential diagnosis of lung carcinoma with coherent anti-Stokes Raman scattering imaging
    Liang Gao
    Department of Systems Medicine and Bioengineering, The Methodist Hospital Research Institute, Houston, Texas, USA
    Arch Pathol Lab Med 136:1502-10. 2012
    ..Finally, we also introduce the potential of a coherent anti-Stokes Raman scattering-based endoscopy system to support intraoperative applications at the cellular level...
  15. ncbi Well-differentiated Papillary Mesothelioma With Invasive Foci
    Andrew Churg
    Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada Department of Pathology, The University of Texas Medical Branch Galveston Department of Pathology and Genomic Medicine, Houston Methodist Hospital Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY PhenoPath Laboratories, Seattle, WA Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Scottsdale, AZ Department of Pathology, University of Virginia Health System, Charlottesville, VA Department of Pathology, CHU Caen, Caen, France Department of Clinical Pathology, Ospedale dell Angelo Venezia, Mestre, Italy
    Am J Surg Pathol 38:990-8. 2014
    ..We suggest that these lesions be called WDPM with invasive foci to alert clinicians to the possibility of recurrence. ..
  16. ncbi Frozen section of lung specimens
    Anna Sienko
    Department of Pathology, The Methodist Hospital, Houston, Texas 77030, USA
    Arch Pathol Lab Med 129:1602-9. 2005
    ..Frozen section of lung tissue is performed to guide the surgeon in subsequent therapy...
  17. ncbi Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of beta-catenin and cyclin D1 expression
    Lizmarie Andino
    Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston Medical School, Houston, Tex, USA
    Arch Pathol Lab Med 130:1503-9. 2006
    ..Alterations of the adenomatous polyposis coli/beta-catenin pathway have been detected in sporadic desmoid tumors and have been associated with nuclear accumulation of beta-catenin and overexpression of cyclin D1...
  18. ncbi Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer
    Alvaro C Laga
    Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    Arch Pathol Lab Med 129:1113-7. 2005
    ..Cyclooxygenase 2 inhibitors have been reported to effectively inhibit carcinogenesis in colon cancer experimental models...
  19. ncbi Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients
    Elizabeth McQuitty
    From the Department of Pathology, University of Texas Health Sciences Center, San Antonio Drs Zhang and Jagirdar the Department of Anatomic and Clinical Pathology, South Texas Veterans Health Care System, San Antonio Dr Tio and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas Drs McQuitty, Olsen, and Cagle and Ms Hendrickson Dr McQuitty is now with the Department of Pathology and Immunology, Baylor College of Medicine, Houston
    Arch Pathol Lab Med 138:390-4. 2014
    ..However, little information addresses the underlying genetic changes in lung adenocarcinoma among Hispanic patients in the United States...
  20. pmc Decreased necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a multiple gene virulence axis
    Randall J Olsen
    Center for Molecular and Translational Human Infectious Disease Research, The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 107:888-93. 2010
    ..Our discovery has broad implications for the confluence of population genomics and molecular pathogenesis research...
  21. doi Advances in treatment of lung cancer with targeted therapy
    Philip T Cagle
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX, USA
    Arch Pathol Lab Med 136:504-9. 2012
    ..To date, 4 targeted therapies have been approved for treatment of lung cancer by the US Food and Drug Administration: gefitinib in 2002, erlotinib in 2003, bevacizumab in 2006, and crizotinib in 2011...
  22. ncbi Localized malignant mesothelioma
    Timothy Craig Allen
    Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    Am J Surg Pathol 29:866-73. 2005
    ..Localized malignant mesotheliomas should be separated from diffuse malignant mesotheliomas because of their localized presentation, quite different biologic behavior, and far better prognosis...
  23. doi Pulmonary sclerosing papillary adenoma
    Timothy Craig Allen
    Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA
    Pathol Int 63:364-7. 2013
    ..We present a case of pulmonary sclerosing papillary adenoma, with extensive sclerotic stroma and scattered areas containing typical papillary architecture. ..
  24. doi On-the-spot lung cancer differential diagnosis by label-free, molecular vibrational imaging and knowledge-based classification
    Liang Gao
    Weill Cornell Medical College, The Methodist Hospital Research Institute, Department of Systems Medicine and Bioengineering, Houston, Texas 77030, USA
    J Biomed Opt 16:096004. 2011
    ..The demonstration of the strategy is also a necessary step toward in vivo point-of-care diagnosis of precancerous and cancerous lung lesions with a fiber-based CARS microendoscope...
  25. ncbi Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma
    Laura A Granville
    U T MD Anderson Cancer Center, Houston, TX, USA
    Appl Immunohistochem Mol Morphol 13:75-9. 2005
    ..Neither antibody performed well on sarcomatous malignant mesothelioma (Zymed=2/22; DAKO=1/22). Both antibodies are useful in the diagnosis of epithelial malignant mesothelioma, although monoclonal antibody is slightly less sensitive...
  26. pmc Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates
    Randall J Olsen
    Center for Molecular and Translational Human Infectious Diseases Research, The Methodist Hospital Research Institute, The Methodist Hospital, and University of Houston, B490, 6565 Fannin Street, Houston, TX 77030, USA
    Am J Pathol 176:1346-54. 2010
    ..We conclude that PVL does not contribute to lower respiratory tract infection in this nonhuman primate model of human CA-MRSA pneumonia...
  27. pmc Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma
    Wei Li
    Department of Pathology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    J Exp Clin Cancer Res 27:2. 2008
    ..This study aims to evaluate immunohistochemical expression of the AMACR in neoplastic and nonneoplastic liver lesions, and assess its value in the diagnosis of hepatocellular carcinoma (HCC)...
  28. ncbi The 100-year anniversary of the description of the frozen section procedure
    Anthony A Gal
    Department of Pathology and Laboratory Medicine, Emory University Hospital, Room H171, 1364 Clifton Rd NE, Atlanta, GA 30322, USA
    JAMA 294:3135-7. 2005
  29. ncbi Silicone thorax due to a ruptured breast implant
    Robert L Levine
    Department of Neurosurgery, The University of Texas School of Medicine, Houston, USA
    Chest 127:1854-7. 2005
    ....
  30. ncbi Pulmonary and ophthalmic involvement with Erdheim-Chester disease: a case report and review of the literature
    Timothy Craig Allen
    Department of Pathology, University of Texas Health Center at Tyler, Houston, Tex 75708 3154, USA
    Arch Pathol Lab Med 128:1428-31. 2004
    ..Immunostains are diagnostically useful, showing immunopositivity for CD68 and factor XIIIa and immunonegativity for CD1a. Birbeck granules are uniformly absent ultrastructurally...
  31. ncbi Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach
    Hong Zhang
    Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston Medical School, Houston, TX 77030, USA
    Mod Pathol 18:111-8. 2005
    ..This panel also facilitates diagnosis of combined small cell and non-small cell carcinomas...